Abstract PS4-12-26: Neosaci-io: neoadjuvant sacituzumab govitecan (sg) + pembrolizumab (pb) in patients (pts) with early-stage tnbc experiencing suboptimal response to keynote-522
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: C. Yam, T. Iwase, B. Nelson, R. L. Bassett, A. Singareeka, G. Whitman, M. Karuturi, B. Adrada, D. Kizub, M. Guirguis, A. Buzdar, T. Moseley, A. Nwosu-Iheme, M. Kapoor, J. Sukumar, P. Thomas, C. H. Barcenas, N. Ibrahim, G. Moscol, A. Nasrazadani, D. Ramirez, M. Wright, J. Lee, W. A. Woodward, J. K. Litton, K. K. Hunt, S. Giordano, D. Tripathy, V. Valero, L. Huo, G. M. Rauch, N. T. Ueno
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129230082